Indivior PLC stock (GB00BYZ0C031): Opioid-treatment specialist faces DOJ settlement while preparing US relisting

Indivior PLC has agreed in principle to a major civil settlement with the US Department of Justice and is progressing toward a planned primary listing in the United States. What this means for the addiction-treatment specialist’s stock and business model.

Indivior PLC, a specialty pharmaceutical company focused on addiction treatment, has moved a step closer to resolving long-running US legal issues and is simultaneously preparing for a planned primary listing in the United States. On May 9, 2025, the group announced that it had reached an agreement in principle with the US Department of Justice (DOJ) to settle remaining civil claims related to legacy marketing practices for its opioid-dependence treatment Suboxone, according to Indivior press release as of 05/09/2025. Earlier, Indivior had also set out steps to shift its main share listing from London to the United States to reflect the company’s revenue focus on the US market, as reported in a separate strategic update published on July 25, 2024 by the company on its investor relations site, according to Indivior press release as of 07/25/2024.

As of: 05/21/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Indivior
• Sector/industry: Pharmaceuticals, addiction treatment
• Headquarters/country: Richmond, Virginia, United States
• Core markets: United States, selected international markets
• Key revenue drivers: Opioid-use disorder medicines, particularly extended?release formulations
• Home exchange/listing venue: London Stock Exchange (LSE), ticker INDV
• Trading currency: GBp (British pence)

Indivior PLC: core business model

Indivior PLC focuses on developing and commercializing medicines for the treatment of substance-use disorders and serious mental illnesses, with its primary business centered on opioid-use disorder therapies. The company’s strategy is to offer pharmacological treatment options that help patients transition away from illicit opioids and maintain recovery, often in combination with counseling and psychosocial support, according to a description of its mission and portfolio in the company’s 2023 annual report, which was published on March 14, 2024 on its investor relations website, as noted by Indivior annual report as of 03/14/2024.

The group’s flagship products are buprenorphine-based medicines for opioid-use disorder, including extended-release injectable therapies that are designed to improve adherence and reduce the risk of misuse compared with some older formulations. These treatments are typically prescribed within structured treatment programs and are reimbursed by public and private payers, particularly in the United States where the opioid crisis has led to sustained demand for evidence?based treatment options, according to background information shared in Indivior’s product overview and market commentary in its full-year 2023 results presentation released on February 15, 2024, as reported by Indivior press release as of 02/15/2024.

In addition to opioid-use disorder, Indivior has been expanding its pipeline into other areas such as alcohol-use disorder and mental health conditions, a strategy the firm describes as building a broader addiction-treatment and behavioral?health franchise. The company invests in clinical research to support label expansions and new formulations and seeks to leverage its relationships with addiction specialists, treatment centers, and payers to drive adoption of newly approved products. This multi-pronged approach aims to diversify revenue beyond a small number of key medicines while still focusing on areas where the company believes there is significant unmet medical need, as outlined in management’s strategic priorities section in its 2023 annual report published in March 2024, according to Indivior annual report as of 03/14/2024.

While the business is global, the United States remains the company’s largest market by a wide margin, with US sales accounting for a substantial majority of revenue in 2023, as the company disclosed in its full-year reporting for 2023 released in February 2024, reported by Indivior press release as of 02/15/2024. This exposure to the US healthcare system, reimbursement dynamics, and regulatory environment shapes much of Indivior’s commercial strategy and is a key factor behind its proposed primary listing move to the US.

Main revenue and product drivers for Indivior PLC

Indivior’s revenue base is heavily driven by sales of long?acting injectable buprenorphine treatments for opioid-use disorder, which the company markets largely to addiction-treatment clinics and specialist physicians in the US. In its full-year 2023 results published on February 15, 2024, Indivior reported that net revenue for 2023 increased versus 2022, supported by growth in its extended-release buprenorphine product, which the company described as its primary growth engine, according to Indivior press release as of 02/15/2024. The company also indicated that demand was driven by increased access initiatives and favorable reimbursement coverage in key US payer segments.

A second major revenue contributor is the company’s portfolio of sublingual buprenorphine products, including both branded and authorized generic offerings that are marketed for maintenance treatment of opioid dependence. These products face ongoing generic competition, which has exerted pricing pressure over the years, but the company has used contracting strategies and product differentiation to protect market share in specific patient groups, according to management comments in the 2023 annual report published March 14, 2024, as outlined by Indivior annual report as of 03/14/2024. The firm’s strategy appears to be to manage this legacy portfolio for cash while investing in newer, higher?margin formulations.

Beyond opioid-use disorder, Indivior has also been working to develop and commercialize treatments for alcohol-use disorder and other psychiatric conditions, aiming to leverage its expertise in chronic behavioral-health diseases. For example, in its research and development update released together with full-year 2023 results on February 15, 2024, the company highlighted progress in late?stage clinical programs targeting alcohol-use disorder and indicated that it sees potential for these candidates to open incremental revenue streams if they secure regulatory approval, according to Indivior press release as of 02/15/2024. However, these pipeline assets are still subject to clinical and regulatory risk, and timelines and commercial potential will depend on trial outcomes and payer acceptance.

Indivior’s margin profile is influenced by a mix of factors, including product mix, research and development spending, and legal expenses. The company’s 2023 results commentary emphasized that operating profit was affected by litigation and compliance costs but also pointed to underlying earnings strength once these items are adjusted for, as stated in the 2023 annual report published in March 2024, according to Indivior annual report as of 03/14/2024. Going forward, the outcome of the DOJ settlement and related legal matters will play an important role in shaping the company’s cost base and free-cash-flow profile.

Legal overhang and DOJ settlement: what investors should know

Indivior’s stock story has for years been shaped by legal proceedings in the United States related to its historical marketing of Suboxone, a buprenorphine-based treatment for opioid dependence. On May 9, 2025, the company announced that it had reached an agreement in principle with the US Department of Justice to resolve civil claims under the False Claims Act for a payment of up to $385 million over several years, subject to final documentation and court approval, according to Indivior press release as of 05/09/2025. The company indicated that it had already recorded provisions related to the matter, meaning that the settlement would largely utilize existing reserves.

In the same announcement, Indivior stated that the agreement would, once finalized, resolve the vast majority of remaining federal civil claims tied to the Suboxone marketing investigation, though certain state?level or private actions could still continue, as noted by Indivior press release as of 05/09/2025. Management presented the development as a major milestone in reducing legal uncertainty and enabling the company to focus more fully on its commercial and research strategy.

The proposed settlement follows earlier resolutions of criminal and civil allegations, including a July 24, 2020 agreement under which Indivior’s former parent company and Indivior itself resolved certain federal criminal charges and related claims, as documented in a press release issued that same day and cited by US Department of Justice as of 07/24/2020. While those earlier settlements addressed criminal exposure and resulted in substantial payments, the May 2025 agreement in principle targets remaining civil liabilities and is expected to further clarify the company’s long?term legal obligations.

For equity investors, the key issues are the size of the remaining cash outflows, the duration over which settlement payments would be spread, and the extent to which provisions on the balance sheet already cover these amounts. In its full-year 2023 financial statements published March 14, 2024, Indivior disclosed significant provisions related to legal matters, noting that ultimate outcomes could differ from current estimates, according to Indivior annual report as of 03/14/2024. As details of the final DOJ settlement documentation become public, market participants will be able to refine their forecasts for future cash flows and leverage.

Planned US primary listing and relevance for American investors

In addition to legal developments, Indivior has been reshaping its capital?markets footprint. On July 25, 2024, the company announced its intention to seek a primary listing in the United States, citing the fact that the majority of its revenue and operations are based there and arguing that a US listing could broaden its investor base and improve trading liquidity, according to Indivior press release as of 07/25/2024. The company indicated that it expected to maintain a meaningful presence on the London Stock Exchange during a transition period but ultimately position the US as its main listing venue.

In that July 2024 statement, Indivior said it would explore a range of options for its US listing, including a potential listing on a major US exchange such as Nasdaq or the New York Stock Exchange, subject to market conditions and regulatory approvals, as reported by Indivior press release as of 07/25/2024. For American investors, a primary US listing could make it easier to trade Indivior shares directly in US dollars during US market hours, without relying on over?the?counter instruments or international trading platforms.

The move toward a US primary listing aligns with Indivior’s operating footprint, as the US opioid-use disorder market is its largest revenue contributor. It could also position the company alongside a broader set of US?listed specialty pharmaceutical peers, potentially changing the way analysts and investors benchmark its valuation metrics. However, a US listing would also increase Indivior’s visibility within a highly regulated and litigious market, potentially heightening scrutiny from investors, regulators, and advocacy groups. This trade?off between improved access to capital and heightened expectations is an important consideration for global shareholders, as emphasized in the July 2024 strategic communication, according to Indivior press release as of 07/25/2024.

For US-based portfolio managers and individual investors focused on healthcare, Indivior’s potential US primary listing would provide a more straightforward way to gain exposure to the opioid-treatment segment through a company with a concentrated focus on addiction medicine. It would also place the stock within major US healthcare and biotech indices if the company eventually meets inclusion criteria, which could influence demand from index funds and exchange?traded products over time. The exact timeline and structure of the listing shift will depend on regulatory review and shareholder approvals, and Indivior has signaled that it will provide further updates as milestones are reached, as indicated in its July 2024 announcement, according to Indivior press release as of 07/25/2024.

Conclusion

Indivior PLC stands at an important crossroads, balancing the opportunities of a growing US market for opioid-use disorder treatments against the challenges of legal settlements and heightened regulatory scrutiny. The May 2025 agreement in principle with the US Department of Justice over Suboxone-related civil claims, if finalized as outlined, would remove a significant legal overhang and offer greater visibility on future cash outflows, according to Indivior press release as of 05/09/2025. At the same time, the planned move toward a primary US listing reflects the company’s operational reality and could make the stock more accessible for US investors focused on healthcare and addiction treatment. Against this backdrop, the investment case depends on how successfully Indivior can grow its long?acting injectable franchise, advance its pipeline, and manage legal and competitive risks in a complex therapeutic area that remains central to public?health debates in the United States.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.